Cencora, Inc. filings document material events for a NYSE-listed pharmaceutical distribution and healthcare solutions company. Recent 8-K disclosures furnish quarterly operating results, Regulation FD information, executive officer transition details, annual meeting voting results and entries into material definitive agreements.
The company’s regulatory record also covers capital-structure matters, including common stock and listed senior notes, registered public debt offerings and the terms of multiple senior note maturities. Governance filings describe director elections and other shareholder voting matters, while material-event reports connect financing activity and completed acquisitions to the company’s operating and financial disclosures.
Ryerkerk Lori reported acquisition or exercise transactions in this Form 4 filing.
Cencora, Inc. director Lori Ryerkerk reported receiving an equity award of 557 shares of common stock in the form of restricted stock units. The units were granted for no cash consideration and will vest 100% on the first anniversary of the grant date.
Following this award, Ryerkerk’s directly held common stock equivalent position increased to 1,073 shares, reflecting her updated ownership after the grant and before any future vesting or settlement events.
Cencora, Inc. reported the results of its 2026 Annual Meeting of Shareholders held on March 5, 2026. Shareholders elected eleven directors, with support for each nominee generally ranging from about 163 million to 168 million votes in favor, with relatively few votes against or abstentions.
Shareholders also approved, on an advisory basis, the fiscal 2025 compensation of the company’s named executive officers, with 156,852,214 votes for, 11,422,390 against, and 427,407 abstentions. In addition, they ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal 2026, with 165,700,999 votes for, 12,622,687 against, and 116,893 abstentions.
Cencora, Inc. President & CEO Robert P. Mauch exercised and sold company stock in related moves. He exercised a non-qualified stock option for 3,762 shares on February 20, 2026 at an exercise price of $86.09 per share, receiving common stock. On the same day, he sold 3,762 common shares in an open-market transaction at an average price of $358.94 per share. Following these transactions, his directly held common stock position was 65,393 shares. The option had become exercisable in four equal installments on November 13, 2020, 2021, 2022, and 2023.
Cencora, Inc. President & CEO Robert P. Mauch reported an open-market sale of 1,333 shares of common stock on February 18, 2026. The shares were sold at a price of $359.46 per share. After this transaction, his reported direct holdings total 65,393 common shares.
Robert P. Mauch reported proposed and completed sales of Common stock.
The filing shows proposed sale of 3,762 shares via an option-related transaction dated 02/20/2026 (method: cash). It also lists completed sales: 5,096 shares on 12/18/2025$1,750,221.20, 5,096 shares on 01/20/2026$1,807,704.08, and 1,333 shares on 02/18/2026$479,160.18.
COR reported proposed sales of common stock by a holder under Rule 144. The filing lists three sales by Robert Mauch: 11/18/2025 5,096 shares for $1,868,397.44; 12/18/2025 5,096 shares for $1,750,221.20; and 01/20/2026 5,096 shares for $1,807,704.08.
The excerpt also records restricted stock vesting entries dated 11/09/2024 (587 shares) and 11/10/2024 (746 shares) attributed to issuer compensation.
Cencora has agreed to merge its animal health business, MWI Animal Health, with Covetrus, valuing MWI at an enterprise value of $3.5 billion. At closing, Cencora will receive $1.25 billion in cash plus equity in the combined parent, including $800 million of perpetual preferred units and $1.45 billion of common units.
After the merger closes and regulatory and other customary conditions are met, Cencora expects to own about 34.3% of the combined CVET TopCo, LP as a non‑controlling shareholder. Cencora notes that its fiscal 2026 guidance does not assume the transaction will close within its 2026 fiscal year.
Cencora, Inc. completed a public offering of $3.0 billion of unsecured senior notes across five tranches, with coupons ranging from 3.950% to 5.650% and maturities from 2029 to 2056. The notes are issued under a long-standing indenture with U.S. Bank Trust Company as trustee and include standard covenants on liens, sale-leasebacks, and mergers, plus customary events of default that can accelerate repayment.
Cencora intends to use the net proceeds to repay amounts outstanding under its 364-Day Term Credit Agreement, which helped fund its acquisition of OneOncology, and to use any remaining funds for general corporate purposes. This transaction replaces short-term acquisition financing with longer-term fixed-rate debt.
Cencora, Inc. is issuing $3.0 billion of unsecured senior notes in five tranches maturing between 2029 and 2056, with fixed coupons ranging from 3.950% to 5.650%. Interest will be paid semi‑annually, and the notes rank equally with Cencora’s other unsecured, unsubordinated debt and are structurally subordinated to subsidiary liabilities.
Cencora expects net proceeds of about $2.98 billion, which it intends to use to repay in full its $3.0 billion 364‑Day Term Loan Facility used to help fund the approximately $4.6 billion acquisition of OneOncology, with any remaining funds for general corporate purposes.
The notes are redeemable at Cencora’s option (including make‑whole and par call structures) and must be offered for repurchase at 101% of principal plus accrued interest if a defined Change of Control Triggering Event occurs. The securities will be issued in book‑entry form and are not expected to be listed on any exchange.
Cencora, Inc. has priced a multi-tranche senior notes offering totaling $3.0 billion, issuing five series of senior unsecured notes maturing between 2029 and 2056 with coupons ranging from 3.950% to 5.650% in an underwritten registered public offering.
Cencora expects to receive approximately $2.98 billion in net proceeds and plans to use the funds primarily to repay borrowings under its $3.0 billion 364-Day Term Loan Facility used to help finance the OneOncology acquisition, with any remaining proceeds earmarked for general corporate purposes.